An informational overview examining category context, publicly available product disclosures, and what consumers often ...

The price of the popular GLP-1 medications will be cut, starting in January of 2027, manufacturer Novo Nordisk said in a ...

That rival is Danish pharmaceutical company Novo Nordisk, best-known for its Wegovy obesity treatment that directly competes with Eli Lilly's Zepbound. Early Tuesday morning, Novo Nordisk announced a ...

Click in for more news from The Hill {beacon} Health Care   The Big Story Novo Nordisk plans to slash GLP-1 prices The list ...

Novo Nordisk will cut prices of the diabetes and weight loss drugs Ozempic, Rybelsus and Wegovy to $675 effective Jan. 1, 2027.

Amid efforts on several fronts to improve the affordability of its GLP-1 medications for diabetes and obesity, Novo Nordisk is taking a new approach by aiming straight for semaglutide’s list price. | ...

The healthcare company said all doses will shift to a single monthly list price, cutting Wegovy’s price by about 50% and ...

Novo Nordisk announced Tuesday it will be slashing the list price of its blockbuster GLP-1 medications, Ozempic, Wegovy and Rybelsus, by up to 50 percent beginning next year. Starting on Jan. 1, ...

Make sure the clinician knows what other medications you’re taking, and set up a real follow-up plan to adjust these ...

You walk into any drugstore today, and the shelves are packed with medications you can grab without a prescription. Seems ...